Carregant...
Fitxers
Tipus de document
ArticleVersió
Versió publicadaData de publicació
Llicència de publicació
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/182875
The Rheumatology drugs for COVID-19 management: Which and when?
Títol de la revista
Director/Tutor
ISSN de la revista
Títol del volum
Recurs relacionat
Resum
Introduction: While waiting for the development of specific antiviral therapies and vaccines to effectively neutralize the SARS-CoV2, a relevant therapeutic strategy is to counteract the hyperinflammatory status, characterized by an increase mainly of interleukin (IL)-1β, IL-2, IL-6, IL-7, IL-8, and tumor necrosis factor (TNF)-α, which hallmarks the most severe clinical cases. 'Repurposing' immunomodulatory drugs and applying clinical management approved for rheumatic diseases represents a game-changer option. In this article, we will review the drugs that have indication in patients with COVID-19, including corticosteroids, antimalarials, anti-TNF, anti-IL-1, anti-IL-6, baricitinib, intravenous immunoglobulins, and colchicine. The PubMed, Medline, and Cochrane Library databases were searched for English-language papers concerning COVID-19 treatment published between January 2020 and October 2020. Results were summarized as a narrative review due to large heterogeneity among studies. In the absence of specific treatments, the use of immunomodulatory drugs could be advisable in severe COVID-19 patients, but clinical outcomes are still suboptimal. An early detection and treatment of the complications combined with a multidisciplinary approach could allow a better recovery of these patients
Citació
Citació
ATZENI, Fabiola, MASALA, Ignazio francesco, RODRÍGUEZ CARRIÓ, Javier, RÍOS GARCÉS, Roberto, GERRATANA, Elisabetta, CORTE LA, Laura, GIALLANZA, Manuela, NUCERA, Valeria, RIVA, Agostino, ESPINOSA GARRIGA, Gerard, CERVERA I SEGURA, Ricard. The Rheumatology drugs for COVID-19 management: Which and when?. _Journal of Clinical Medicine_. 2021. Vol. 10, núm. 4, pàgs. 783. [consulta: 24 de gener de 2026]. ISSN: 2077-0383. [Disponible a: https://hdl.handle.net/2445/182875]